U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[_] Check box if no longer subject of Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
________________________________________________________________________________
1. Name and Address of Reporting Person*
Chase Venture Capital Associates, LLC ("CVCA, LLC")
--------------------------------------------------------------------------------
(Last) (First) (Middle)
c/o Chase Capital Partners
1221 Avenue of the Americas-40th Floor
--------------------------------------------------------------------------------
(Street)
New York New York 10020
--------------------------------------------------------------------------------
(City) (State) (Zip)
________________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
Praecis Pharmaceuticals Incorporated ("PRCS")
________________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
________________________________________________________________________________
4. Statement for Month/Year
November 2000
________________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
================================================================================
6. Relationship of Reporting Person to Issuer
(Check all applicable)
[_] Director [X] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
________________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form filed by one Reporting Person
[X] Form filed by more than one Reporting Person
________________________________________________________________________________
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ------------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 11/2/00 S 27,500 D $30.24 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/2/00 S 400,000 D $31.44 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/3/00 S 200,000 D $27.99 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/3/00 S 100,000 D $28.74 4,839,004 D
-----------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/3/00 S 200,000 D $28.12 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/3/00 S 100,000 D $28.99 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/3/00 S 100,000 D $29.49 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/3/00 S 100,000 D $29.62 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/3/00 S 100,000 D $29.74 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 75,000 D $31.37 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 205,000 D $31.49 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 25,000 D $31.62 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 15,000 D $30.68 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 45,000 D $30.49 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 50,000 D $31.24 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 145,000 D $31.12 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 25,000 D $30.87 4,839,004 D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/6/00 S 15,000 D $30.62 4,839,004 D
====================================================================================================================================
</TABLE>
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
(Print or Type Responses)
(Over)
(Form 4-07/99)
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
================================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
or Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
---------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
$7.00
per Common
Options share N/A N/A N/A N/A (FN 1) 1/11/01 Stock 9,166 N/A 9,166 I (FN 1)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Explanation of Responses:
(1) These options were granted to Dr. Damion Wicker, a general partner of Chase
Capital Partners, which is the general partner of the managing member and the
manager, by delegation, of the reporting person. Dr. Wicker is contractually
obligated to exercise the options at the request of CVCA, LLC, and to transfer
any shares issued under the stock options to CVCA, LLC. The options originally
had a term of ten years from the date of the grant and vested and became
exercisable in equal monthly installments over a three-year period so long as
Dr. Wicker continued to be a member of the Board of Directors of the Issuer.
As of October 13, 2000, Dr. Wicker ceased to be a director of the Issuer.
Options with respect to 9,166 shares had vested as of that date; these options
remain exercisable until the 90th day from the date of his resignation.
Chase Venture Capital Associates, LLC
By: Chase Capital Partners, as Investment Manager
/s/ Jeffrey C. Walker 12/08/00
By: -------------------------------------------- -----------------------
Jeffrey C. Walker Date
Managing General Partner of Chase Capital Partners
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF DESIGNATED STATEMENT ISSUER NAME, TICKER
REPORTING PERSON REPORTER (Note 1) FOR OR TRADING SYMBOL
MONTH/YEAR
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
John R. Baron Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Christopher C. Behrens Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
-----------------------------------------------------------------------------------------------------------------------------
Mitchell J. Blutt Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
David S. Britts Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
50 California Street
San Francisco, CA
94111
------------------------------------------------------------------------------------------------------------------------------------
Arnold L. Chavkin Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
David J. Gilbert Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Eric A. Green Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Michael R. Hannon Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF TITLE OF AMOUNT OF OWNERSHIP FORM: NATURE OF INDIRECT DISCLAIMS
REPORTING PERSON SECURITY SECURITIES DIRECT (D) OR BENEFICIAL OWNERSHIP PECUNIARY
BENEFICIALLY INDIRECT (I) INTEREST
OWNED
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
John R. Baron See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Christopher C. See Tables I and II See Tables I and II I See Explanatory No
Behrens Note 2 below
c/o Chase Capital
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Mitchell J. Blutt See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
David S. Britts See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
50 California Street
San Francisco, CA
94111
------------------------------------------------------------------------------------------------------------------------------------
Arnold L. Chavkin See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
David J. Gilbert See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Eric A. Green See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Michael R. Hannon See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
-1-
<PAGE>
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF DESIGNATED STATEMENT ISSUER NAME, TICKER
REPORTING PERSON REPORTER (Note 1) FOR OR TRADING SYMBOL
MONTH/YEAR
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Donald J. Hofmann Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
-------------------------------------------------------------------------------------------------------
Jonathan Meggs Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
125 London Wall
London EC2Y 5AJ,
United Kingdom
------------------------------------------------------------------------------------------------------------------------------------
Stephen P. Murray Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Thomas Mendell Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
John M.B. O'Connor Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Robert Rugggiero
c/o Chase Capital Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
Partners Capital Associates,
1221 Avenue of the Americas LLC
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Susan L. Segal Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Shahan D. Soghikian Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
50 California
Street, Suite 2940
San Francisco, CA
94111
------------------------------------------------------------------------------------------------------------------------------------
Lindsay Stuart Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
125 London Wall
London EC2Y 5AJ,
United Kingdom
------------------------------------------------------------------------------------------------------------------------------------
Patrick Sullivan Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Charles R. Walker Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
One Bush Street, 12th Fl
40th Floor
San Francisco, CA 94104
------------------------------------------------------------------------------------------------------------------------------------
Jeffrey C. Walker Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF TITLE OF AMOUNT OF OWNERSHIP FORM: NATURE OF INDIRECT DISCLAIMS
REPORTING PERSON SECURITY SECURITIES DIRECT (D) OR BENEFICIAL OWNERSHIP PECUNIARY
BENEFICIALLY INDIRECT (I) INTEREST
OWNED
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Donald J. Hofmann See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Jonathan Meggs See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
125 London Wall
London EC2Y 5AJ,
United Kingdom
------------------------------------------------------------------------------------------------------------------------------------
Thomas Mendell See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Stephen P. Murray See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
John M.B. O'Connor See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Robert Rugggiero See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Susan L. Segal See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Shahan D. Soghikian See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
50 California
Street, Suite 2940
San Francisco, CA
94111
------------------------------------------------------------------------------------------------------------------------------------
Lindsay Stuart See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
125 London Wall
London EC2Y 5AJ,
United Kingdom
------------------------------------------------------------------------------------------------------------------------------------
Patrick Sullivan See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Charles R. Walker See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
One Bush Street, 12th Fl
San Francisco, CA 94104
------------------------------------------------------------------------------------------------------------------------------------
Jeffrey C. Walker See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
-2-
<PAGE>
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF DESIGNATED STATEMENT ISSUER NAME, TICKER
REPORTING PERSON REPORTER(Note 1) FOR OR TRADING SYMBOL
MONTH/YEAR
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Timothy J. Walsh Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Richard D. Waters Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Damion E. Wicker Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Eric R. Wilkinson Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
CCP European Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
Principals, LLC Capital Associates,
c/o Chase Capital LLC
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
CCP Principals, LLC
c/o Chase Capital Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
Partners Capital Associates,
1221 Avenue of the Americas LLC
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Chase Capital Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
Corporation Capital Associates,
c/o Chase Capital LLC
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
The Chase Manhattan Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
Corporation Capital Associates,
270 Park Avenue LLC
35th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Chase Capital Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
Partners Capital Associates,
1221 Avenue of the Americas LLC
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
CCP-SBIC Manager, LLC Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Chatham Ventures, Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
Corporation c/o Chase Capital Associates,
Capital Partners LLC
1221 Avenue of the Americas
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF TITLE OF AMOUNT OF OWNERSHIP FORM: NATURE OF INDIRECT DISCLAIMS
REPORTING PERSON SECURITY SECURITIES DIRECT (D) OR BENEFICIAL OWNERSHIP PECUNIARY
BENEFICIALLY INDIRECT (I) INTEREST
OWNED
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Timothy J. Walsh See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Richard D. Waters See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Damion E. Wicker See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 3 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Eric R.Wilkinson See Tables I and II See Tables I and II I See Explanatory Yes
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
CCP European See Tables I and II See Tables I and II I See Explanatory No
Principals, LLC Note 2 below
c/o Chase Capital
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
CCP Principals, LLC See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 2 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Chase Capital See Tables I and II See Tables I and II I See Explanatory No
Corporation Note 2 below
c/o Chase Capital
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
The Chase Manhattan See Tables I and II See Tables I and II I See Explanatory No
Corporation Note 4 below
270 Park Avenue
35th Floor
New York, NY 10017
------------------------------------------------------------------------------------------------------------------------------------
Chase Capital See Tables I and II See Tables I and II I See Explanatory No
Partners Note 5 below
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
CCP-SBIC Manager, LLC See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 6 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Chatham Ventures, Inc. See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 7 below
Partners
1221 Avenue of the Americas
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
-3-
<PAGE>
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF DESIGNATED STATEMENT ISSUER NAME, TICKER
REPORTING PERSON REPORTER(Note 1) FOR OR TRADING SYMBOL
MONTH/YEAR
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
David L. Ferguson Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
I. Robert Greene Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Flatiron Capital Associates,
Partners LLC
257 Park Avenue
South 15th Floor
New York, NY 10010
------------------------------------------------------------------------------------------------------------------------------------
Brian J. Richmand Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Jonas Steinmann Chase Venture November, 2000 Praecis Pharmaceuticals Incorporated ("PRCS")
c/o Chase Capital Capital Associates,
Partners LLC
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
NAME AND ADDRESS OF TITLE OF AMOUNT OF OWNERSHIP FORM: NATURE OF INDIRECT DISCLAIMS
REPORTING PERSON SECURITY SECURITIES DIRECT (D) OR BENEFICIAL OWNERSHIP PECUNIARY
BENEFICIALLY INDIRECT (I) INTEREST
OWNED
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
David L.Ferguson See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 8 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
I. Robert Greene See Tables I and II See Tables I and II I See Explanatory No
c/o Flatiron Note 9 below
Partners
257 Park Avenue
South 15th Floor
New York, NY 10010
------------------------------------------------------------------------------------------------------------------------------------
Brian J. Richmand See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 10 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
Jonas Steinmann See Tables I and II See Tables I and II I See Explanatory No
c/o Chase Capital Note 11 below
Partners
1221 Avenue of the Americas
40th Floor
New York, NY 10020
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
Explanatory Notes:
1) The Designated Reporter is executing this report on behalf of all reporting
persons, each of whom has authorized it to do so.
2) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because the reporting person is a partner
of Chase Capital Partners ("CCP"), which is (a) the sole managing member of
CCP-SBIC Manager, LLC ("CCP-SBIC"), the sole managing member of CVCA, LLC and
(b) the manager, by delegation, of CVCA, LLC pursuant to an advisory agreement
with CCP-SBIC. The actual pro rata portion of such beneficial ownership that
may be deemed to be attributable to the reporting person is not readily
determinable because it is subject to several variables, including the internal
rate of return and vesting of interests within CCP and CVCA, LLC.
3) Until October 13, 2000, the reporting person was a director of the Issuer.
The amounts shown in Tables I and II represent the beneficial ownership of the
Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because he is a general partner of CCP,
the sole managing member of CCP-SBIC and the manager, by delegation, of
CVCA, LLC. The actual pro rata portion of such beneficial ownership is not
readily determinable because it is subject to several variables, including the
internal rate of return and vesting of interests within CCP and CVCA, LLC.
4) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because it is (a) the sole stockholder of
Chase Capital Corporation, a general partner of CCP, the sole managing member
of CCP-SBIC and the manager, by delegation, of CVCA, LLC and (b) the sole
stockholder of the non-managing member of CVCA, LLC. The actual pro rata
portion of such beneficial ownership that may be attributable to the reporting
person is not readily determinable because it is subject to several variables,
including the internal rate of return and vesting of interests within CCP and
CVCA, LLC.
5) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because it is (a) the sole managing member
of CCP-SBIC, the sole managing member of CVCA and (b) the manager, by
delegation, of CVCA, LLC pursuant to an advisory agreement with CCP-SBIC. The
actual pro rata portion of such beneficial ownership that may be deemed to be
attributable to the reporting person is not readily determinable because it is
subject to several variables, including the internal rate of return and vesting
of interests within CCP and CVCA, LLC.
6) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because it is the sole managing member of
CVCA, LLC. The actual pro rata portion of such beneficial ownership that may
be deemed to be attributable to the reporting person is not readily determinable
because it is subject to several variables, including the internal rate of
return and vesting of interests within CVCA, LLC.
7) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because it is the non-managing member of
CVCA, LLC. The actual pro rata portion of such beneficial ownership that may be
deemed to be attributable to the reporting person is not readily determinable
because it is subject to several variables, including the internal rate of
return and vesting of interests within CVCA, LLC.
8) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because he was a general partner of CCP,
the sole managing member of CCP-SBIC and the manager, by delegation, of CVCA,
LLC, until June 1, 1997. The actual pro rata portion of such beneficial
ownership that may be deemed to be attributable to the reporting person is not
readily determinable because it is subject to several variables, including the
internal rate of return and vesting within CCP and CVCA, LLC.
9) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because he was a general partner of CCP,
the sole managing member of CCP-SBIC and the manager, by delegation, of CVCA,
LLC, until May 31, 1999. The actual pro rata portion of such beneficial
ownership that may be deemed to be attributable to the reporting person is not
readily determinable because it is subject to several variables, including the
internal rate of return and vesting within CCP and CVCA, LLC.
10) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because he was a general partner of
CCP, the sole managing member of CCP-SBIC and the manager, by delegation, of
CVCA, LLC, until December 31, 1999. The actual pro rata portion of such
beneficial ownership that may be deemed to be attributable to the reporting
person is not readily determinable because it is subject to several variables,
including the internal rate of return and vesting within CCP and CVCA, LLC.
11) The amounts shown in Tables I and II represent the beneficial ownership of
the Issuer's equity securities by CVCA, LLC, a portion of which may be deemed
attributable to the reporting person because he was a general partner of CCP,
the sole managing member of CCP-SBIC and the manager, by delegation, of CVCA,
LLC, until July 1, 1999. The actual pro rata portion of such beneficial
ownership that may be deemed to be attributable to the reporting person is not
readily determinable because it is subject to several variables, including the
internal rate of return and vesting within CCP and CVCA, LLC.
-5-
